New drugs target Glioblastoma's growth pathways in early brain study
NCT ID NCT05798507
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 35 times
Summary
This early-phase trial studies how two oral drugs, defactinib and VS-6766, enter glioblastoma tumors and the surrounding brain tissue. Fourteen adults with new or recurrent glioblastoma who need surgery will take a single dose of one drug before their tumor is removed. The main goals are to measure drug levels in the tumor and blood and to check for side effects. This is a knowledge-gathering study, not a treatment trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.